RxDoctor Payments Data

Fiona Mudge, MD

Psychiatry · Randolph, MANPI 1417933888

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,798 and has fallen 98.1% since, to $34 in 2025. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,618in general payments, 2019–2025

Across 439 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$881
  • Neurocrine Biosciences, Inc.$814
  • Otsuka America Pharmaceutical, Inc.$758
  • Lundbeck LLC$570
  • Teva Pharmaceuticals USA, Inc.$488
  • plus $3K from 14 others

What the payments were for

  • Food & beverage$7,49598%
  • Education$1232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,618 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$23,078
Medicare patients
46
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZyprexaOlanzapine12$11,732
Aripiprazole13$5,756
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$3,049
Bupropion XlBupropion Hcl40$909
Venlafaxine Hcl ErVenlafaxine Hcl33$764
Trazodone Hcl57$602
Quetiapine Fumarate13$553
Lorazepam81$508
Sertraline Hcl29$469
Fluoxetine Hcl15$409
Divalproex Sodium ErDivalproex Sodium13$332
Clonazepam44$319
Topiramate19$271
Mirtazapine22$267
Methylphenidate Hcl26$263

Paid to pharmacies, not to this prescriber.

Other psychiatry in Randolph

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →